Robert A. Newman, Ph.D., President, Chief Science Officer, Chairman of the Scientific Advisory Board, and Director. Dr. Newman obtained his M.S. and Ph.D. degrees in Pharmacology and Toxicology from the University of Connecticut and then served in postdoctoral positions at the Medical School of the University of Georgia as well as the Department of Biochemistry at the University of Vermont. He served as a faculty member at the University of Vermont Medical School for seven years and then spent a sabbatical year at Stanford University performing research on immune targeted therapy. He spent 24 years at the University of Texas M. D. Anderson Cancer Center (MDACC) in Houston, Texas where he held the D. B. Lane Distinguished Professorship Chair. At MDACC he served as the founder and Co-Director of the Pharmaceutical Development Center and the institution's Analytical Center. He has published over 320 articles dealing with the preclinical and clinical pharmacology, toxicology and development of therapies for the prevention and treatment of malignant diseases.
Crandell Addington, Chief Executive Officer, Chairman, and Director. Mr. Addington is a cum laude graduate from Southwestern University, Georgetown, Texas, majoring in economics and accounting. Mr. Addington received post-graduate education in various sciences at Trinity University, San Antonio, Texas. Mr. Addington has, over the course of 40 years, founded and/or operated successful enterprises ranging from chemical manufacturing to oil and gas exploration, development, and production. Mr. Addington is also President and Chairman of the Board of Anviram, Inc. As a result of his prior and current corporate leadership positions, Mr. Addington has been responsible, among other duties, for interacting with biomedical researchers and clinicians both in the United States and Latin America.
Lou Kost, Jr., Executive Vice President, Secretary and Director. Mr. Kost attended the University of Texas at Austin, and St. Mary's University in San Antonio, Texas, where he studied marketing and financial management. Mr. Kost has been at various times a venture capitalist and management consultant. Mr. Kost is a former Texas state representative who served on the Banking Committee. Mr. Kost is currently a Director and Secretary of Anviram, Inc. Among other duties, Mr. Kost is responsible for interacting with investment bankers and the shareholders of the Company.
Jeffrey Thompson, Director. Mr. Thompson is an early investor who was asked to serve as the company's first outside director when Phoenix was formed in 2003. He is an attorney and currently lives in Des Moines, Iowa. He is employed with the Iowa Department of Justice, where he serves as Deputy Attorney General. Prior to his appointment to this position in 2008, Mr. Thompson was in private practice and specialized in civil litigation.
Andrew J. Butler, Director. Mr. Butler is Vice Chairman of Cottingham & Butler, Inc. and President of SISCO and HealthCorp. Prior, he was Chief Executive Officer and President of both Butler Insurance Service, Inc. and Butler Benefit Service, Inc. He is currently a Trustee of Junior Achievement of the Heartland and on the board of the Dubuque Museum of Art. He has served as the President of the Board of Trustee’s for the Figge Art Museum, was a Director for the Third Party Administrators of America Association (TPAAA), and has service in an advisory capacity to several public and privately held organizations for both product development and managerial development matters. He earned his MBA from The College of Insurance in New York City, his BS in Finance from Babson College and holds several industry designations, Including CPCU, CEBS, CSFS, and ARM.
Macdonald T. Haskell, Director. Mr. Haskell is President of MTH Ventures, Inc., a company primarily involved in private investments and entrepreneurial endeavors. Mac began his career in New York at Merrill Lynch and Co. and earned his B.A. in Economics from Hobart College in 1980. He lives in Ponte Vedra Beach, FL with his wife and two daughters.